A2A 02
Alternative Names: A2A-02; A2A-O-02; A2A_O-02; Protein-protein interaction inhibitor - A2A Pharmaceuticals; Yap-Tead inhibitors - A2A PharmaceuticalsLatest Information Update: 01 Dec 2023
At a glance
- Originator A2A Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 01 Dec 2023 A2A 02 is still in early research for Solid tumours in USA (A2A Pharmaceuticals pipeline, December 2023)
- 28 Aug 2023 No recent reports of development identified for research development in Solid-tumours in USA
- 26 Nov 2021 A2A Pharmaceuticals announces intention to submit IND for Solid tumours in the first half of 2023 (A2A Pharmaceuticals pipeline, November 2021)